<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>243102</rcn>
  <id>101101050</id>
  <acronym>MUC-BITE</acronym>
  <teaser>Colorectal carcinoma (CRC) is one of the leading causes of cancer death in women and men. CRC can be broadly subdivided into adenocarcinoma-type and mucinous-type CRC, characterised by an overproduction of mucin proteins which is the primary component of mucus. These mucins...</teaser>
  <objective>Colorectal carcinoma (CRC) is one of the leading causes of cancer death in women and men. CRC can be broadly subdivided into adenocarcinoma-type and mucinous-type CRC, characterised by an overproduction of mucin proteins which is the primary component of mucus. These mucins form a 'physical barrier' that impedes the accessibility of current CRC therapies to their target receptors, limiting what would otherwise be promising cancer drugs.
Dr. Karin Strijbis' group has discovered a compelling mucinase enzyme that can effectively degrade the mucin barrier. Preliminary research performed by Dr. Strijbis' group revealed this mucinase's therapeutic potential to enhance the effectivity of approved anti-CRC drugs (i.e., anti-EGFR antibodies and small molecule inhibitors) by demonstrating the removal of obstructive mucin proteins and a decrease in CRC cell proliferation. 
In MUC-BITE, we present Nano-MUCase, a novel biological based on the conjugation of this mucinase with a nanobody to selectively target CRC tumours for optimal delivery and removal of the mucin barrier. During this PoC project, we will determine the technical and commercial feasibility Nano-MUCase through the following activities: 
1.	Validate the capabilities of the Nano-MUCase to target CRC tumours and reduce mucin interference of anti-CRC drugs in organoid samples and in vivo.
2.	Define an IP strategy by performing a thorough IP landscape and patentability analysis.
3.	Conduct market research to discover potential customers/industrial partners, analyse competitors and identify a feasible roadmap to commercialisation.
4.	Formulate a detailed business case to guide the commercialisation of the Nano-MUCase to penetrate the market and deliver a new therapeutic strategy to benefit CRC patients.</objective>
  <title>Mucinase-based innovative therapy to enhance cancer treatment</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>150000</ecMaxContribution>
  <startDate>2023-01-01</startDate>
  <endDate>2024-12-31</endDate>
  <ecSignatureDate>2022-11-18</ecSignatureDate>
  <duration>24</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101101050</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2024-12-31 09:30:22</sourceUpdateDate>
  <contentCreationDate>2022-11-25 10:01:43</contentCreationDate>
  <contentUpdateDate>2022-11-25 10:01:38</contentUpdateDate>
  <lastUpdateDate>2025-09-19 14:49:06</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>439640</rcn>
        <id>439640-novel-colorectal-cancer-targeted-treatment</id>
        <title>Novel colorectal cancer targeted treatment</title>
        <contentUpdateDate>2023-04-24 17:10:01</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55606</rcn>
        <title>ERC-2022-POC2</title>
        <identifier>ERC-2022-POC2</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55606</rcn>
        <title>ERC-2022-POC2</title>
        <identifier>ERC-2022-POC2</identifier>
      </call>
      <organization netEcContribution="150000" totalCost="0" source="corda" order="1" ecContribution="150000" terminated="false" sme="false" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1905698</rcn>
        <id>999985805</id>
        <vatNumber>NL001798650B01</vatNumber>
        <legalName>UNIVERSITEIT UTRECHT</legalName>
        <shortName>UU</shortName>
        <address>
          <street>HEIDELBERGLAAN 8</street>
          <city>Utrecht</city>
          <postalCode>3584 CS</postalCode>
          <country>NL</country>
          <postBox>N/A</postBox>
          <url>http://www.uu.nl</url>
          <geolocation>52.0851807,5.1754514</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode>/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <rcn>1471669</rcn>
              <nutsCode>NL350</nutsCode>
            </region>
            <region type="relatedRegion">
              <name>Netherlands</name>
              <rcn>391547432</rcn>
              <nutsCode>NL</nutsCode>
              <euCode>NL</euCode>
              <isoCode>NL</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>706736</rcn>
        <id>HORIZON_ERC-2022-POC2</id>
        <code>ERC-2022-POC2</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC PROOF OF CONCEPT GRANTS2</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1335518</rcn>
        <id>101101050_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - MUC-BITE (Mucinase-based innovative therapy to enhance cancer treatment)</title>
        <description>periodic</description>
        <teaser>Colorectal carcinoma (CRC) is the second and third most common cause of cancer death in women and men, respectively, causing a significant burden on the European patient population.1 CRC can be broadly subdivided into adenocarcinoma-type CRC (aCRC) and mucinous-type CRC...</teaser>
        <sourceUpdateDate>2025-07-21 16:50:46</sourceUpdateDate>
        <contentUpdateDate>2025-07-21 16:50:46</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode>/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/315/997/1613/1617</code>
        <title>enzymes</title>
        <displayCode>/natural sciences/biological sciences/biochemistry/biomolecules/proteins/enzymes</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-ERC-POC</code>
        <title>HORIZON ERC Proof of Concept Grants</title>
        <description>HORIZON ERC Proof of Concept Grants</description>
        <displayCode>/HORIZON ERC Proof of Concept Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>